Latest Breaking News On - Diagnostics development dxd hub - Page 1 : comparemela.com
ASEAN countries strengthen pandemic research cooperation
universityworldnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from universityworldnews.com Daily Mail and Mail on Sunday newspapers.
PH, Singapore co-leading ASEAN study on regional populations immune response to COVID-19 vaccination – Manila Bulletin
mb.com.ph - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mb.com.ph Daily Mail and Mail on Sunday newspapers.
Singapore enhances neutralizing antibody testing service
Singapore enhances neutralizing antibody testing service 12 April 2021 | News
Image credit- prnewswire
GenScript Biotech Corporation, Parkway Laboratories and the Diagnostics Development (DxD) Hub announced their collaboration to provide the cPass™ SARS-CoV-2 neutralizing antibody test in Singapore through Parkway s panel of specialist and GP clinics.
Neutralizing antibodies are a small percentage of antibodies that bind to sites on the virus and inhibit entry of that virus into the host. Unlike the many COVID-19 lab-based antibody test kits commercially available, cPass™ can detect functional neutralizing antibodies.
Traditionally, measuring neutralizing antibodies requires the use of live virus, cells, highly skilled operators, and complex laboratory procedures that require several days in the laboratory to obtain results and limit their widespread use.
Share:
APPROVAL ALLOWS
RESOLUTE 2.0 TEST KIT TO BE USED WITH A VARIETY OF TESTING METHODS – INCLUDING DEEP-THROAT SALIVA, OROPHARYNGEAL/MIDDLE TURBINATE AND NASOPHARYNGEAL TEST SWABS
RESOLUTE 2.0 WILL BE USED AT SINGAPORE CHANGI AIRPORT WITH THE NEW ON-SITE ADDITION OF A COVID-19 TESTING LAB IN 2021.
Advanced MedTech Holdings (AMTH), a global medical technology leader headquartered in Singapore, announced today that the RESOLUTE 2.0 test kit has become the first RT-PCR COVID-19 test to be authorised by Singapore s Health Sciences Authority (HSA) for deep-throat saliva (DTS) SARS-CoV-2 testing.
The clinical performance of DTS is supported by clinical studies involving the Diagnostics Development (DxD) Hub hosted by the Agency for Science, Technology and Research (A STAR); Temasek Foundation; Changi General Hospital (CGH); DSO National Laboratories (DSO); and Woodlands Health Campus (WHC). The tests conducted on DTS specimens were able to accurately identify all the known